

Zanidatamab (ZW25) in HER2-expressing Gastroesophageal Adenocarcinoma (GEA): Results from a Phase 1 Study

Funda Meric-Bernstam¹; Erika Hamilton²; Murali Beeram³; Diana Hanna⁴; Anthony El-Khoueiry⁴; Yoon-Koo Kang⁵; Keun-Wook Lee⁶; Jeeyun Lee⁷; Sun Young Rha⁸; Jose Chaves⁹; Do-Youn Oh; Rachel Goodwin¹¹; Jaffer Ajani¹; Todd Gray¹²; Joseph Woolery¹²; Elena Elimova¹³

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; ³The START Center for Cancer Care, San Antonio, TX, US; ⁴USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA; ⁵Asan Medical Center, Seoul, South Korea; ⁶Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea; ⁷Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul Korea; ⁸Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea; ⁹Northwest Medical Specialties, Tacoma, WA, USA; ¹⁰Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; ¹¹University of Ottawa Cancer Centre, Ottawa, ON, Canada; ¹²Zymeworks Inc., Vancouver, BC, Canada; ¹³Princess Margaret Cancer Centre, Toronto, ON, Canada

Corresponding author: fmeric@mdanderson.org


(Data extracted on Nov 16, 2020 from an unlocked database and subject to change)

Background

- Human epidermal growth factor receptor 2 (HER2) is overexpressed in ~20% of gastroesophageal adenocarcinoma (GEA)^{1,2}
- For patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma:
 - trastuzumab in combination with chemotherapy is the only approved HER2-targeted therapy³
 - treatment options are limited if disease progression occurs after HER2-targeted therapy

Zanidatamab: Bispecific HER2-targeted Antibody

- A biparatopic antibody that simultaneously binds two distinct sites on HER2: ECD4 (trastuzumab-targeted domain) and ECD2 (pertuzumab-targeted domain)
- Unique trans-binding results in multiple mechanisms of action by zanidatamab, including enhanced receptor clustering and internalization



ECD=extracellular domain.

1, Abrahao-Machado, *et al.* World J Gastroenterol . 2016 May 21;22(19):4619-25; 2, Van Cutsem, *et al.* Gastric Cancer. 2015 Jul;18(3):476-84;

3, HERCEPTIN® (trastuzumab). South San Francisco (CA): Genentech, Inc.; 2018. Prescribing Information.

ZW25-101 (NCT02892123)


Key Study Objectives

- To characterize the safety and tolerability, and potential anti-tumor effects of zanidatamab, both as monotherapy and in combination with select chemotherapy

Patient Population

- Patients with HER2-expressing cancers, including GEA
- Progression after standard of care therapy
- ECOG performance status of 0 or 1
- Measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Fresh or archived tumor tissue available for central review of HER2 status

Study Design (GEA Focused)



BID=twice daily; DLT=dose-limiting toxicity; GEA=gastroesophageal adenocarcinoma; IV=intravenous; MTD=maximum-tolerated dose; PS=performance status; QW=weekly; Q2W=every 2 weeks; RECIST=Response Evaluation Criteria in Solid Tumors; RD=recommended dose; wks=weeks.

GEA Patient Characteristics

- The majority of patients had received at least two prior systemic regimens, including trastuzumab

	Zanidatamab Monotherapy ^a (N = 35)	Zanidatamab + Chemotherapy Combination	
		Zanidatamab ^b + Pac (N = 11)	Zanidatamab ^c + Cape (N = 17)
Median age, year (range)	62 (24–86)	61 (25–80)	63 (26–79)
Sex: Male, n (%)	28 (80)	10 (91)	12 (71)
Race, n (%)			
White	19 (54)	7 (64)	10 (59)
Asian	12 (34)	4 (36)	7 (41)
Other	5 (14) ^d	0	0
Initial diagnosis, n (%)			
Esophageal	5 (14)	2 (18)	2 (12)
Gastroesophageal junction	9 (26)	2 (18)	6 (35)
Gastric	21 (60)	7 (64)	9 (53)
HER2: IHC3+ or IHC2+/FISH+, n (%)	31 (89)	7 (64)	8 (47)
Median prior systemic therapies (range)	3 (0–7)	3 (1–7)	2 (1–5)
Patients with prior HER2-targeted therapies, n (%)	32 ^e (91)	10 ^f (91)	15 ^f (88)

Note: Data extracted on: Nov 16, 2020 (data are from an unlocked database and subject to change). Cape= capecitabine; Pac=paclitaxel.

a, included 10 mg/kg QW and 20 mg/kg Q2W; b, 20 mg/kg Q2W; c, included 20 mg/kg Q2W and 30 mg/kg Q3W; d, included Black or African (n=2), American Indian or Alaska Native (n=2), and unknown (n=1); e, all of these patients received prior trastuzumab, 1 patient each also received prior neratinib and T-DM1; f, all received prior trastuzumab.

Safety: Treatment-related^a (AEs)

- The majority^a of treatment-related^b AEs were Grade 1 or 2 in severity and manageable in the outpatient setting


	Zanidatamab Monotherapy (N = 35)		Zanidatamab + Chemotherapy Combination			
	Any Grade	Grade 3 or higher	Zanidatamab + Pac (N = 11)		Zanidatamab + Cape (N = 17)	
	Any Grade	Grade 3 or higher	Any Grade	Grade 3 or higher	Any Grade	Grade 3 or higher
Patients with treatment-emergent AEs, n (%)	34 (97)	17 (49)	11 (100)	9 (82)	17 (100)	10 (59)
Patients with treatment-related AEs	25 (71)	4 (11)	11 (100)	7 (64)	15 (88)	2 (12)
Most common AEs ^c						
Diarrhea	16 (46)	1 (3)	7 (64)	0	10 (59)	0
Infusion-related reaction	12 (34)	0	3 (27)	0	0	0
Nausea	4 (11)	0	4 (36)	0	3 (18)	0
Fatigue	4 (11)	0	7 (64)	2 (18)	3 (18)	0

- Treatment-related serious AEs reported in 3 patients: Grade 3 diarrhea (zanidatamab monotherapy), Grade 5 pneumonitis (zanidatamab + paclitaxel), and Grade 2 creatinine increased (zanidatamab + capecitabine)

AE=adverse event.


a, 95% of treatment-related AEs with zanidatamab monotherapy or zanidatamab + capecitabine, and 80% with zanidatamab + paclitaxel, were Grade 1 or 2 in severity; b, related to zanidatamab and/or chemotherapy; c, zanidatamab-related AEs occurring in ≥ 10% of patients in the zanidatamab monotherapy group.

Anti-tumor Activity: Zanidatamab Monotherapy



E=esophageal; FISH=fluorescence in situ hybridization; G=gastric; IHC=immunohistochemistry; J=gastroesophageal junction; K=T-DM1; N=Neratinib; T=trastuzumab; Tx=treatment. 33 (94%) patients were response-evaluable; 3 patients had no post-baseline tumor measurements and are not included in this plot.


Anti-Tumor Activity: Zanidatamab + Chemotherapy



E=esophageal; FISH=fluorescence in situ hybridization; G=gastric; IHC=immunohistochemistry; J=gastroesophageal junction; K=T-DM1; N=Neratinib; T=Trastuzumab; Tx=treatment.

24 (86%) patients were response-evaluable; 2 patients had no post-baseline tumor measurements and are not included in this plot.

Duration of Treatment: Zanidatamab + Chemotherapy



(c)PR=(confirmed) partial response; CR=complete response; FISH=fluorescence in situ hybridization; IHC=Immunohistochemistry; PD=progressive disease; SD=stable disease; T=Trastuzumab; Tx=treatment.

▼, Clinical progression; *, Death; ◆, Continued study treatment for clinical benefit.

Disease Response per RECIST 1.1 in Response-Evaluable^a Patients

	Zanidatamab Monotherapy (N = 33)	Zanidatamab + Chemotherapy Combination		
		Zanidatamab + Pac (N = 10)	Zanidatamab + Cape (N = 14)	Combo Total (N = 24)
Confirmed objective response ^b , n (%)	11 (33)	5 (50)	8 (57)	13 (54)
Complete response	0	1 (10)	0	1 (4)
Partial response	11 (33)	4 (40)	8 (57)	12 (50)
Stable disease	9 (27)	4 (40)	2 (14)	6 (25)
Progressive disease	13 (39)	1 (10)	4 (29)	5 (21)
Disease control rate, n (%)	20 (61)	9 (90)	10 (71)	19 (79)
Duration of response, ^c months	(N=11)	(N=5)	(N=8)	(N=13)
Median (95% CI)	6.0 (1.9, 9.2)	9.1 (5.6, NE)	5.8 (3.5, NE)	8.9 (5.6, NE)
PFS, months	(N=35 ^d)	(N=11 ^e)	(N=17 ^f)	(N=28 ^g)
Median (95% CI)	3.6 (1.9, 6.2)	10.9 (3.4, 12.4)	5.4 (1.5, 7.7)	5.6 (3.0, 10.9)

PFS=progression-free survival; NE=not estimable.

a, all treated patients with measurable disease who had at least one evaluable, post-baseline disease assessment (per RECIST 1.1) or discontinued study treatment due to death or clinical progression; b, per investigator assessment using RECIST 1.1; c, in response evaluable patients who had a confirmed complete or partial response followed by ≥1 response assessment; d, safety set (5 pts were censored); e, safety set (3 pts were censored); f, safety set (6 pts were censored); g, safety set (9 pts In total were censored).

Conclusions

- Zanidatamab is well tolerated with promising anti-tumor activity in patients with HER2-expressing GEA that has progressed after prior therapies, including HER2-targeted agents
 - The majority of the treatment-related AEs were Grade 1 or 2 and manageable in the outpatient setting
 - Durable responses and disease control with zanidatamab as monotherapy and in combination with chemotherapy
 - Zanidatamab monotherapy: Confirmed ORR: 33%; DCR: 61%; median DOR: 6.0 months
 - Zanidatamab + chemotherapy: Confirmed ORR: 54%; DCR:79%; median DOR: 8.9 months
- Based on these data, zanidatamab is being further evaluated in patients with HER2-expressing GEA in 2 global studies:
 - ZW25-201 (Phase 2; NCT03929666): zanidatamab + 1st line chemotherapy in patients with HER2-expressing GEA
 - BGB-A317-ZW25-101 (Phase 1b/2; NCT04276493): zanidatamab in combination with chemotherapy with/without tislelizumab in patients with HER2+ GEJ adenocarcinoma and breast cancer

DOR, duration of response; DCR=disease control rate; GEJ=gastroesophageal junction, NE=not estimable; ORR=objective response rate.

Acknowledgments and Other Information

Acknowledgments

We sincerely thank all patients and their families. Thanks to all the investigators, clinical trial researchers, personnel and staff who contributed to the trial in any way.

Thanks also to Dr. Michael Press and Ms. Ivonne Villalobos at USC Medical Center Pathology Lab for support of HER2 testing.

Sponsor

ZW25-101 study is sponsored by Zymeworks Inc.

ZW25-201 study is sponsored by Zymeworks Inc.

BGB-A317-ZW25-101 study is sponsored by BeiGene, Ltd.